Gastroenterology Search
Gastroenterology Gastroenterology
constipation%20in%20adults%20-%20chronic%20functional
CONSTIPATION IN ADULTS - CHRONIC FUNCTIONAL
Constipation is an unsatisfactory defecation distinguished by difficult stool passage, infrequent stools or both.
Difficult stool passage may include straining, feeling of difficulty in passing stool, incomplete evacuation, lumpy/hard stools, prolonged time to defecate, need for manual maneuver to pass stool, abdominal discomfort and feeling of anorectal blockade.
Chronic constipation is considered when symptoms of constipation have existed ≥3 months.
Symptoms of chronic constipation may be due to dysfunction of intestinal motility, visceral sensitivity, anorectal musculature or the enteric nervous system.

Constipation in Adults - Chronic Functional Drug Information

Drug Information

Indication: Spasmodic pain, oesophageal spasm, cholecystitis, choledocholithiasis, dysuria & pollakisuria, spasmodic d...

Indication: Acute spasm, as in renal or biliary chronic, radiology for differential diagnosis of obstruction. Reduce spasm...

Indication: Relief of constipation eg, constipation in pregnancy & maintenance of regularity. Bowel function managemen...

Indication: Constipation, hepatic encephalopathy.

Indication: Myasthenia gravis.

Indication: Constipation & portal systemic encephalopathy.

Senokot
sennoside B

Indication: Relief of constipation & bowel evacuation prior to radiological exam.

2  /  4
2  /  4
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Durable treatment response seen with dapagliflozin-saxagliptin add-on in T2D patients on metformin
Audrey Abella, 25 Nov 2020
Reductions in liver fat and adipose tissue volumes were sustained in patients with type 2 diabetes (T2D) with the addition of the SGLT-2* inhibitor dapagliflozin (DAPA) and the DPP-4** inhibitor saxagliptin (SAXA) to metformin (MET), compared with a regimen comprising glimepiride (GLIM)+MET, according to the extension period results of a phase IIIb trial.